Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Apr 13, 2023 10:04am
140 Views
Post# 35392784

RE:RE:RE:Eurk!

RE:RE:RE:Eurk!That info is just what I had hoped would not be released but was afraid the heads management wins, tails shareholders lose deal would be in place as is typically the case across the corporate world. However, the salary info is not something that could have been adjusted as the bad cancer news came out on the first day of the fiscal 2023 year and that money had already been paid. SGA expenses in the first quarter were pretty flat so perhaps they instituted a salary freeze for 2023, admittedly at an already very high level. The cash bonuses is perhaps where they could have made an adjustment although I am not certain when those are paid. But if THTX was indeed blindsided by the pause news, it is possible those were already paid before the end of the fiscal year and, therefore, before the pause news. It would be good to hear that big adjustments to executive compensation have been made in 2023 but given they made sure to hold the first quarter conference call a day before teh proxy was released, I suspect that may not be the case.

 

palinc2000 wrote:

I know the CEO is in a difficult position  caused by many factors some of  which may not be his fault but for Ch+**st  sake just basic human decency would have dictated at minimum a FREEZE in compensation for management and Board Members and a decrease in the number of Directors .
 

Show some compassion not your personal greed


palinc2000 wrote:

I suggest you read the compensation related info during Happy Hour ...... snd make it a double!!!



 


 



<< Previous
Bullboard Posts
Next >>